Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2018, Article ID 9369358, 9 pages
https://doi.org/10.1155/2018/9369358
Research Article

Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer

1College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, Republic of Korea
2Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence should be addressed to Ja Seung Koo; ca.shuy@6791sjk

Received 20 June 2017; Accepted 17 January 2018; Published 25 February 2018

Academic Editor: Fabrizia Bamonti

Copyright © 2018 Junjeong Choi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Riganti, E. Gazzano, M. Polimeni, E. Aldieri, and D. Ghigo, “The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate,” Free Radical Biology & Medicine, vol. 53, no. 3, pp. 421–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Zhang, Z. Zhang, Y. Zhu, and S. Qin, “Glucose-6-phosphate dehydrogenase: a biomarker and potential therapeutic target for cancer,” Anti-Cancer Agents in Medicinal Chemistry, vol. 14, no. 2, pp. 280–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Lucarelli, V. Galleggiante, M. Rutigliano et al., “Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma,” Oncotarget, vol. 6, no. 15, pp. 13371–13386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. J. E. Kwon, W. H. Jung, and J. S. Koo, “Molecules involved in epithelial-mesenchymal transition and epithelial-stromal interaction in phyllodes tumors: implications for histologic grade and prognosis,” Tumour Biology, vol. 33, no. 3, pp. 787–798, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. C. M. Perou, T. Sørlie, M. B. Eisen et al., “Molecular portraits of human breast tumours,” Nature, vol. 406, no. 6797, pp. 747–752, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 19, pp. 10869–10874, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Reis-Filho and A. N. J. Tutt, “Triple negative tumours: a critical review,” Histopathology, vol. 52, no. 1, pp. 108–118, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Pinheiro, B. Sousa, A. Albergaria et al., “GLUT1 and CAIX expression profiles in breast cancer correlate with adverse prognostic factors and MCT1 overexpression,” Histology and Histopathology, vol. 26, no. 10, pp. 1279–1286, 2011. View at Publisher · View at Google Scholar
  9. J. Choi, W. H. Jung, and J. S. Koo, “Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry,” Pathobiology, vol. 80, no. 1, pp. 41–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Kim, D. H. Kim, W.-H. Jung, and J. S. Koo, “Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer,” Endocrine Related Cancer, vol. 20, no. 3, pp. 339–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Y. Jung, Y. K. Lee, and J. S. Koo, “Expression of cancer-associated fibroblast-related proteins in adipose stroma of breast cancer,” Tumor Biology, vol. 36, no. 11, pp. 8685–8695, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. C. W. Elston and I. O. Ellis, “Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up,” Histopathology, vol. 19, no. 5, pp. 403–410, 1991. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. H. Hammond, D. F. Hayes, M. Dowsett et al., “American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer,” Journal of Clinical Oncology, vol. 28, no. 16, pp. 2784–2795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. C. Wolff, M. E. Hammond, J. N. Schwartz et al., “American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 118–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. R. Henry, H. O. Lee, J. S. Lee et al., “Clinical implications of fibroblast activation protein in patients with colon cancer,” Clinical Cancer Research, vol. 13, no. 6, pp. 1736–1741, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Goldhirsch, W. C. Wood, A. S. Coates et al., “Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011,” Annals of Oncology, vol. 22, no. 8, pp. 1736–1747, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Marcell Szász, A. Lánczky, Á. Nagy et al., “Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients,” Oncotarget, vol. 7, no. 31, pp. 49322–49333, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. D. Richardson, C. Yang, A. Osterman, and J. W. Smith, “Central carbon metabolism in the progression of mammary carcinoma,” Breast Cancer Research and Treatment, vol. 110, no. 2, pp. 297–307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. L. Meadows, B. Kong, M. Berdichevsky et al., “Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells,” Biotechnology Progress, vol. 24, no. 2, pp. 334–341, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Yoon, D. H. Kim, and J. S. Koo, “Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer,” Journal of Translational Medicine, vol. 12, no. 1, p. 149, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. S. K. Kim, W. H. Jung, and J. S. Koo, “Differential expression of enzymes associated with serine/glycine metabolism in different breast cancer subtypes,” PLoS One, vol. 9, no. 6, article e101004, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Kim, Y. Lee, and J. S. Koo, “Differential expression of lipid metabolism-related proteins in different breast cancer subtypes,” PLoS One, vol. 10, no. 3, article e0119473, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Manandhar, B.-h. Choi, K.-A. Jung et al., “NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity,” Free Radical Biology & Medicine, vol. 52, no. 9, pp. 1773–1785, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Ahmad, D. Dixit, V. Sharma et al., “Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma,” Cell Death & Disease, vol. 7, no. 5, article e2213, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Harami-Papp, L. S. Pongor, G. Munkácsy et al., “TP53 mutation hits energy metabolism and increases glycolysis in breast cancer,” Oncotarget, vol. 7, no. 41, pp. 67183–67195, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Földi, E. Stickeler, L. Bau et al., “Transketolase protein TKTL1 overexpression: a potential biomarker and therapeutic target in breast cancer,” Oncology Reports, vol. 17, no. 4, pp. 841–845, 2007. View at Publisher · View at Google Scholar
  27. F. P. Kuhajda, K. Jenner, F. D. Wood et al., “Fatty acid synthesis: a potential selective target for antineoplastic therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 14, pp. 6379–6383, 1994. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Vazquez-Martin, R. Colomer, J. Brunet, R. Lupu, and J. A. Menendez, “Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells,” Cell Proliferation, vol. 41, no. 1, pp. 59–85, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Jiang, W. Du, X. Wang et al., “p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase,” Nature Cell Biology, vol. 13, no. 3, pp. 310–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. C. Patra and N. Hay, “The pentose phosphate pathway and cancer,” Trends in Biochemical Sciences, vol. 39, no. 8, pp. 347–354, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Elf, R. Lin, S. Xia et al., “Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin,” Oncogene, vol. 36, no. 2, pp. 254–262, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Catanzaro, E. Gaude, G. Orso et al., “Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death,” Oncotarget, vol. 6, no. 30, pp. 30102–30114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Wang, G. Wu, G. Cao et al., “Zoledronic acid inhibits the pentose phosphate pathway through attenuating the Ras‑TAp73‑G6PD axis in bladder cancer cells,” Molecular Medicine Reports, vol. 12, no. 3, pp. 4620–4625, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Li, M. A. Fath, P. M. Scarbrough, W. H. Watson, and D. R. Spitz, “Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer,” Redox Biology, vol. 4, pp. 127–135, 2015. View at Publisher · View at Google Scholar · View at Scopus